Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

J Allergy Clin Immunol. 2021 Mar;147(3):1107-1109.e2. doi: 10.1016/j.jaci.2020.09.021. Epub 2020 Sep 28.
No abstract available

Publication types

  • Clinical Trial, Phase IV
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Angiotensin-Converting Enzyme 2* / genetics
  • Angiotensin-Converting Enzyme 2* / metabolism
  • Anti-Inflammatory Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • COVID-19 / complications
  • Double-Blind Method
  • Female
  • Gene Expression Regulation
  • Humans
  • Interleukin-17 / metabolism
  • Male
  • Middle Aged
  • Placebo Effect
  • Psoriasis* / drug therapy
  • Skin* / drug effects
  • Skin* / pathology
  • Young Adult

Substances

  • Angiotensin-Converting Enzyme 2
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • secukinumab